Mood Disorders@@@Psychopharmacology
Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, Head, Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, Canada; Chairman and Executive Director, Brain and Cognition Discovery Foundation, Toronto, Canada; Director, Depression and Bipolar Support Alliance, Chicago, Illinois; Professor and Nanshan Scholar, Guangzhou Medical University, Guangzhou, China
Jeffrey Strawn, MD, FAACAP
Associate Professor of Psychiatry & Pediatrics, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio
Breakfast will be served. Seating for these sessions is available on a first come, first-serve basis only. Admittance is based on availability and is not guaranteed. Please plan to arrive early to ensure a seat. Breakfast will only be available until 8:00 AM.
Bipolar depression affects a wide range of populations. There is a broad heterogeneity of presentations that can affect the course of illness and its treatment. As a result, there is no “one size fits all” approach to the management of those with the disorder. Are you well versed in these differences? Then test your knowledge!
World-renowned experts Roger S. McIntyre, MD, from the University of Toronto and Jeffrey R. Strawn, MD, from the University of Cincinnati explore contemporary topics in the management of bipolar depression by evaluating factual and nonfactual assertions. Audience members have the opportunity to test their knowledge using interactive polling to “vote” on each question. After judging the clinical accuracy of each statement, Dr. McIntyre and Dr. Strawn will provide a detailed explanation of the correct response based on the latest evidence-based data. Topics include strategies for recognition and evidence-based treatment of bipolar depression in children and adolescents, challenges in diagnosing and managing bipolar depression in older adults, and complex presentations of depression and subsyndromal hypomania or mania.
Supported by an educational grant from Sunovion Pharmaceuticals Inc.